Measuring performance in clinical rheumatology.
作者信息
Scott D L, Haslock I
机构信息
Department of Rheumatology, St Bartholomew's Hospital, West Smithfield, London.
出版信息
Ann Rheum Dis. 1990 Jan;49(1):3-5. doi: 10.1136/ard.49.1.3.
Abstract
摘要
相似文献
1
Measuring performance in clinical rheumatology.衡量临床风湿病学的表现。
Ann Rheum Dis. 1990 Jan;49(1):3-5. doi: 10.1136/ard.49.1.3.
2
Cost effectiveness analysis--assessing the assumptions behind the assumptions.成本效益分析——评估假设背后的假设。
J Rheumatol. 2000 Jun;27(6):1565-7.
3
Medical audit.医学审计
N Z Med J. 1979 Jun 27;89(638):485-8.
4
Are guidelines good value for money?指南是否物有所值？
Rheumatology (Oxford). 2015 Dec;54(12):2121-3. doi: 10.1093/rheumatology/kev308. Epub 2015 Aug 27.
5
Research methodology in rheumatology.风湿病学研究方法
Acta Orthop Scand Suppl. 2002 Oct;73(305):8-14. doi: 10.1080/000164702760379486.
6
Royal College of Physicians Standing Committee on Rheumatology, and British Society for Rheumatology. Guidelines for the Organization of Audit in Rheumatology: Combined Working Group Report.皇家内科医师学会风湿病学常务委员会及英国风湿病学会。风湿病学审计组织指南：联合工作组报告。
Br J Rheumatol. 1992 May;31(5):333-6. doi: 10.1093/rheumatology/31.5.333.
7
Issues of consensus and debate for economic evaluation in rheumatology.风湿病学中经济评估的共识与争议问题
J Rheumatol. 2001 Mar;28(3):642-7.
8
OMERACT 5 Economics Working Group: summary, recommendations, and research agenda.骨关节炎研究的最小重要临床改变国际工作组5经济学工作组：总结、建议及研究议程
J Rheumatol. 2001 Mar;28(3):670-3.
9
A regional audit of the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the West Midlands.西米德兰兹地区风湿性疾病患者糖皮质激素性骨质疏松症防治情况的区域审计。
Rheumatology (Oxford). 2002 Sep;41(9):1021-4. doi: 10.1093/rheumatology/41.9.1021.
10
Does economic evaluation have anything to offer the rheumatologist?经济评估能为风湿病学家提供什么吗？
Rheumatology (Oxford). 1999 Jan;38(1):2-5. doi: 10.1093/rheumatology/38.1.2.
本文引用的文献
1
2
The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year.类风湿关节炎的自然病史：一项十五年随访研究。第一年所记录特征的预后意义。
Clin Rheumatol. 1984 Mar;3(1):11-20. doi: 10.1007/BF02715690.
3
Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.在对75名类风湿性关节炎患者进行的长达九年的研究中，出现了严重的功能衰退、工作能力丧失以及死亡率增加的情况。
Arthritis Rheum. 1984 Aug;27(8):864-72. doi: 10.1002/art.1780270805.
4
Costs of health care: experience of one department of rheumatology.医疗保健成本：一个风湿病科的经验
Br Med J (Clin Res Ed). 1985 Oct 5;291(6500):957-9. doi: 10.1136/bmj.291.6500.957.
5
The development of disability in rheumatoid arthritis.类风湿关节炎中残疾的发展
Arthritis Rheum. 1986 Apr;29(4):494-500. doi: 10.1002/art.1780290406.
6
The present and future of comprehensive outcome measures for rheumatic diseases.风湿性疾病综合结局指标的现状与未来
Clin Rheumatol. 1987 Sep;6 Suppl 2:105-11. doi: 10.1007/BF02203393.
7
Costs of providing a rheumatological service.提供风湿病学服务的成本。
Br J Rheumatol. 1987 Dec;26(6):454-7. doi: 10.1093/rheumatology/26.6.454.
8
Disability in rheumatoid arthritis: comparison of prognostic factors across three populations.类风湿关节炎中的残疾：三个群体预后因素的比较。
J Rheumatol. 1987 Aug;14(4):705-9.
9
Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.金诺芬治疗类风湿关节炎患者及生活质量。一项多中心试验的结果。
Am J Med. 1986 Oct;81(4):565-78. doi: 10.1016/0002-9343(86)90539-5.
10
What happens to patients with rheumatoid arthritis? The long-term outcome of treatment.类风湿性关节炎患者会怎样？治疗的长期结果。
Clin Rheumatol. 1988 Sep;7(3):315-30. doi: 10.1007/BF02239187.
Zotero 插件